North America Anticancer Drugs/Oncology Drugs Market Overview:
The North America Anticancer Drugs/Oncology Drugs Market size was valued at USD 64,394.03 MN in 2021 and reached USD 87,086.19 MN in 2025. It is anticipated to reach USD 150,370.53 MN by 2032, growing at a CAGR of 6.76% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2021-2024
Base Year
2025
Forecast Period
2025-2032
North America Anticancer Drugs/Oncology Drugs Market Size 2025
USD 87,086.19 million
North America Anticancer Drugs/Oncology Drugs Market, CAGR
6.76%
North America Anticancer Drugs/Oncology Drugs Market Size 2032
USD 150,370.53 million
North America Anticancer Drugs/Oncology Drugs Market Insights
Market growth is supported by rising cancer incidence, accelerated oncology drug approvals, biomarker-based treatment adoption, immunotherapy expansion and increasing use of targeted therapies.
Targeted Therapy holds a strong position because oncology treatment is shifting toward biomarker-driven regimens, molecular testing and precision medicine across major cancer indications.
Immunotherapy continues to gain share as checkpoint inhibitors and combination regimens expand across lung cancer, stomach cancer, colorectal cancer, breast cancer and other cancers.
Hospital Pharmacies remain the leading distribution channel because complex oncology drugs require specialist administration, reimbursement coordination, cold-chain handling and clinical monitoring.
North America Anticancer Drugs/Oncology Drugs Market Segment Insights
By drug class
By drug class, Targeted Therapy held a strong position in 2025 because cancer treatment is increasingly driven by molecular diagnostics, tumor biomarkers and mutation-specific drug selection. These therapies support better patient stratification and are widely used across lung cancer, breast cancer, colorectal cancer, kidney cancer and other oncology indications. Immunotherapy continues to expand as checkpoint inhibitors and combination regimens move into earlier lines of treatment and broader tumor types. Chemotherapy remains relevant because it is still used alone and in combination with immunotherapy, targeted therapy and supportive care drugs. Others include hormonal therapies, radiopharmaceuticals, antibody-drug conjugates and emerging cell and gene-based oncology treatments.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
By indication, Lung Cancer held a strong position in 2025 because it remains one of the largest therapeutic areas for immunotherapy, targeted therapy and chemotherapy combinations. Breast Cancer and Prostate Cancer also account for strong demand due to large patient pools, biomarker-based treatment expansion and high use of long-term systemic therapy. Colorectal Cancer, Stomach Cancer and Liver Cancer are gaining importance as targeted and immunotherapy options expand into more defined patient groups. Kidney Cancer and Bladder Cancer benefit from immuno-oncology regimens and newer targeted combinations. Cervical Cancer, Esophagus Cancer and Other Cancers create additional growth opportunities as oncology drug development broadens across tumor types and treatment settings.
By distribution channel
By distribution channel, Hospital Pharmacies held the strongest position in 2025 because many oncology drugs require infusion, specialist supervision, patient monitoring and coordination with cancer treatment centers. Hospital-based distribution also supports complex biologics, immunotherapies, antibody-drug conjugates and chemotherapy regimens that require controlled handling. Retail Pharmacies remain relevant for oral oncology drugs, supportive care products and maintenance therapies used outside inpatient or infusion settings. Online Pharmacies are gaining gradual traction due to specialty medication fulfillment, home delivery and digital refill management. However, high-value oncology therapies still require strong clinical oversight, reimbursement support and temperature-controlled distribution. Channel growth will favor integrated specialty pharmacy models that connect clinicians, payers and patients.
Key market drivers
Precision oncology and biomarker-led prescribing
Precision oncology and biomarker-led prescribing represent a major growth driver for the North America Anticancer Drugs/Oncology Drugs Market. Treatment decisions increasingly depend on molecular testing, tumor profiling and companion diagnostics that identify patients most likely to respond to a therapy. This shift supports demand for targeted therapies, immunotherapies and antibody-drug conjugates across lung cancer, breast cancer, colorectal cancer, prostate cancer and other cancers. Drug manufacturers benefit when biomarker-defined indications support premium pricing, stronger clinical differentiation and label expansion. Health systems also use precision treatment pathways to improve outcomes and reduce ineffective therapy use. This driver will remain central through 2032 as oncology pipelines focus on smaller but better-defined patient groups.
Immunotherapy and combination regimen expansion
Immunotherapy and combination regimen expansion support market growth as checkpoint inhibitors and immune-based regimens move across more tumor types and treatment lines. Immunotherapy is increasingly used with chemotherapy, targeted therapy, radiation and other immune modulators to improve treatment response. These combinations are especially important in Lung Cancer, Stomach Cancer, Kidney Cancer, Bladder Cancer and Other Cancers. Pharmaceutical companies continue to study new regimens that extend treatment duration and increase total drug utilization per patient. This supports market revenue growth even as competition rises in mature immuno-oncology categories. The driver will remain important as clinical practice adopts more combination and maintenance strategies.
Aging population and higher oncology treatment access
Aging population and higher oncology treatment access continue to strengthen demand for anticancer drugs across North America. Older populations face higher cancer risk, which increases diagnosis, screening, treatment and long-term therapy needs. Expanded insurance coverage, specialty oncology networks and broader access to cancer centers also support treatment volume. Patients increasingly receive systemic therapy for longer periods due to maintenance regimens, adjuvant treatment and metastatic disease management. This supports demand across chemotherapy, targeted therapy, immunotherapy and supportive drug categories. Market growth will remain linked to payer coverage, oncology guideline adoption and improved access to high-cost specialty medicines.
Oral oncology and specialty pharmacy growth
Oral oncology and specialty pharmacy growth are reshaping distribution and treatment delivery. More targeted therapies and maintenance regimens are available in oral formats, which increases the role of Retail Pharmacies, specialty pharmacies and Online Pharmacies. These channels support refill management, adherence programs, payer coordination and patient education. However, oral oncology drugs still require careful monitoring because toxicity, interactions and dose adjustments can affect treatment outcomes. Specialty pharmacy models help bridge hospital-based oncology care and home-based drug administration. This driver will support channel diversification while Hospital Pharmacies remain central for infused and complex therapies.
Key Trends and Opportunities
Antibody-drug conjugates gain stronger adoption
Antibody-drug conjugates are becoming a major opportunity because they combine targeted delivery with cytotoxic payloads to improve tumor-specific treatment. They are expanding across breast cancer, lung cancer, bladder cancer and other tumor types. These drugs can support premium pricing and strong clinical differentiation when they address biomarker-defined populations or patients with limited options. Manufacturers are investing in next-generation linker, payload and antibody designs to improve efficacy and manage toxicity. The category also creates logistics and pharmacy requirements due to infusion administration and controlled handling. Antibody-drug conjugates will remain a high-growth opportunity within targeted oncology.
Radiopharmaceuticals and nuclear oncology expand
Radiopharmaceuticals and nuclear oncology are gaining momentum as targeted radiation therapies expand into prostate cancer and other indications. These therapies require specialized manufacturing, isotope supply, treatment site readiness, radiation safety protocols and trained clinical teams. They offer strong growth potential because they address defined patient groups and can extend treatment options beyond conventional systemic therapy. Pharmaceutical companies are investing in radioligand therapy platforms, supply networks and clinical trials. Distribution complexity can create barriers, but it also supports premium value and specialist provider relationships. The opportunity will grow as more cancer centers build radiopharmaceutical capacity.
Digital specialty pharmacy and adherence programs rise
Digital specialty pharmacy and adherence programs are rising as oral oncology therapies become more common. Patients using oral targeted therapies often need refill reminders, side effect support, financial assistance and monitoring coordination. Digital platforms help pharmacies track adherence, manage prior authorization and connect patients with care teams. Online Pharmacies can support convenience, but oncology medication management requires specialist oversight. Retail and specialty pharmacies that combine digital tools with oncology expertise can gain stronger channel relevance. This trend will support distribution channel diversification through 2032.
Key Market Challenges
High drug cost and payer access pressure
High drug cost and payer access pressure remain key challenges for the North America Anticancer Drugs/Oncology Drugs Market. Many targeted therapies, immunotherapies, antibody-drug conjugates and radiopharmaceuticals carry high treatment costs. Payers increasingly use prior authorization, step therapy, evidence reviews and value-based contracting to manage oncology spending. These controls can slow patient access and increase administrative burden for providers. Drug manufacturers must demonstrate survival benefit, quality-of-life improvement and strong evidence in defined patient populations. Cost pressure will remain a central challenge as more premium oncology drugs enter the market.
Clinical complexity and treatment sequencing
Clinical complexity and treatment sequencing create challenges for oncologists, payers and drug manufacturers. Patients may receive chemotherapy, immunotherapy, targeted therapy, radiopharmaceuticals and supportive treatments across multiple lines of therapy. Biomarker testing, resistance mutations and combination regimens make treatment selection more complex. Sequencing decisions can affect drug utilization, reimbursement and competitive positioning. Manufacturers must generate evidence showing where their therapies fit within changing standards of care. Clear guidelines, real-world evidence and diagnostic integration will become more important.
Manufacturing and supply chain sensitivity
Manufacturing and supply chain sensitivity can affect availability of complex oncology drugs. Biologics, antibody-drug conjugates, radiopharmaceuticals and sterile injectables require specialized production, quality control and cold-chain handling. Supply disruptions can affect treatment schedules and create risks for patients and providers. Radiopharmaceuticals face additional constraints because isotope availability and time-sensitive logistics are critical. Specialty pharmacies and hospital pharmacies must coordinate storage, documentation and dispensing carefully. Companies with resilient manufacturing networks and strong distribution planning will manage this challenge more effectively.
Regional Analysis
United States
The United States leads the North America Anticancer Drugs/Oncology Drugs Market due to its large treated patient base, strong oncology research ecosystem, broad cancer center network and high adoption of premium therapies. The country has strong demand for Targeted Therapy, Immunotherapy, antibody-drug conjugates, radiopharmaceuticals and oral oncology drugs. Hospital Pharmacies and specialty pharmacy networks play a central role because many therapies require complex reimbursement support and clinical monitoring. Drug manufacturers prioritize the U.S. for launches, label expansions and patient support programs because of the size and value of the market. The United States is expected to remain the primary revenue contributor through 2032.
Canada
Canada represents a steady oncology drugs market supported by public health coverage, cancer care networks, specialty pharmacy services and clinical adoption of high-value therapies. Demand is strongest across Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer and other major tumor types. Market access depends on health technology assessment, provincial reimbursement and clinical guideline adoption. Hospital Pharmacies play a major role in oncology drug distribution, while retail and specialty channels support oral cancer therapies. Canada’s market growth will remain linked to reimbursement decisions, biosimilar adoption, precision testing access and patient access programs.
Mexico
Mexico offers a smaller but gradually expanding market within North America. Demand is supported by rising cancer diagnosis, improving private health care access and growing availability of oncology therapies through hospitals and specialty channels. Hospital Pharmacies remain central because complex therapies require oncologist supervision and controlled administration. Retail Pharmacies and private specialty channels support selected oral oncology drugs and supportive treatments. Affordability and reimbursement constraints remain important challenges, especially for premium immunotherapies and targeted therapies. Growth will depend on access expansion, private hospital investment and broader availability of cancer diagnostics.
Report Attribute Details
Report Attribute
Details
Historical Period
2021–2024
Base Year
2025
Forecast Period
2025–2032
Market Size in 2021
USD 64,394.03 MN
Market Size in 2025
USD 87,086.19 MN
Market Size in 2032
USD 150,370.53 MN
CAGR
6.76%
Segments Covered
Drug Class, Indication, Distribution Channel and Geography
Key Companies Covered
AstraZeneca plc, Novartis AG, Merck & Co., Inc., Amgen, Pfizer Inc., AbbVie Inc., Astellas Pharma Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson and Bristol-Myers Squibb Company
Market Segmentations
By Drug Class
Chemotherapy
Targeted Therapy
Immunotherapy
Others
By Indication
Lung Cancer
Stomach Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Esophagus Cancer
Cervical Cancer
Kidney Cancer
Bladder Cancer
Other Cancers
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Key Players
AstraZeneca plc
Novartis AG
Merck & Co., Inc.
Amgen
Pfizer Inc.
AbbVie Inc.
Astellas Pharma Inc.
F. Hoffmann-La Roche Ltd.
Johnson & Johnson
Bristol-Myers Squibb Company
Recent Developments
In June 2026, the FDA approved capivasertib, marketed as Truqap by AstraZeneca, with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive prostate cancer.
In March 2025, the FDA expanded Pluvicto, marketed by Novartis, for adults with PSMA-positive metastatic castration-resistant prostate cancer who had received androgen receptor pathway inhibitor therapy and were considered appropriate to delay taxane-based chemotherapy.
In March 2025, the FDA granted traditional approval to pembrolizumab, marketed as Keytruda by Merck, with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for first-line treatment of HER2-positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1.
In May 2025, the FDA granted accelerated approval to telisotuzumab vedotin-tllv, marketed as Emrelis by AbbVie, for certain adults with previously treated locally advanced or metastatic non-squamous non-small cell lung cancer with high c-Met protein overexpression.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
The research report offers an in-depth analysis based on drug class, indication, distribution channel and geography. It details leading market players, providing an overview of their business positioning, oncology portfolios, pipeline relevance, market access capabilities and strategic role in the North America Anticancer Drugs/Oncology Drugs Market. The report includes insights into the competitive environment, market trends, growth drivers, restraints and opportunities. It also examines precision oncology, biomarker testing, immunotherapy expansion, targeted therapy adoption, specialty pharmacy growth and high-value drug reimbursement as major factors shaping market development. The report assesses the impact of drug cost, treatment sequencing, manufacturing complexity and distribution channel evolution on market growth. It provides strategic recommendations for pharmaceutical companies, hospital systems, specialty pharmacies, payers, distributors, investors and new entrants seeking to navigate North America’s oncology drugs ecosystem.
Future Outlook
Demand for anticancer drugs will continue to rise as oncology treatment shifts toward precision medicine, immunotherapy and targeted regimens.
Targeted Therapy will remain a major drug class because molecular testing and biomarker-defined prescribing continue to expand.
Immunotherapy will gain further adoption across earlier treatment lines and broader tumor types.
Chemotherapy will remain relevant as a combination backbone in several oncology protocols.
Lung Cancer will remain a leading indication due to high use of targeted drugs, immunotherapies and combination regimens.
Breast Cancer and Prostate Cancer will continue to support strong revenue due to long-term systemic treatment and advanced therapy adoption.
Hospital Pharmacies will remain the leading distribution channel for infused, complex and high-value oncology medicines.
Retail Pharmacies and Online Pharmacies will gain relevance as oral oncology drug use expands.
Radiopharmaceuticals and antibody-drug conjugates will create high-value growth opportunities for specialized oncology portfolios.
Competition will increase as leading companies compete on clinical benefit, biomarker strategy, label expansion, market access and patient support programs.
Table of Contents (The complete Toc, LoF and LoT are available in the sample report)
Chapter No. 1: Introduction
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. USP and Key Offerings
1.2. Key Benefits for Stakeholders
1.3. Target Audience
Chapter No. 2: Executive Summary
Chapter No. 3: North America Anticancer Drugs/Oncology Drugs Market Forces and Industry Pulse
3.1. Introduction
3.2. Catalysts of Expansion – Key Market Drivers
3.2.1. Precision oncology and biomarker-led prescribing
3.2.2. Immunotherapy and combination regimen expansion
3.2.3. Aging population and higher oncology treatment access
3.2.4. Oral oncology and specialty pharmacy growth
3.3. Market Restraints
3.3.1. High drug cost and payer access pressure
3.3.2. Clinical complexity and treatment sequencing
3.3.3. Manufacturing and supply chain sensitivity
3.4. Untapped Horizons – Growth Potential and Opportunities; Strategic Navigation – Industry Frameworks
3.4.1. Antibody-drug conjugates gain stronger adoption
3.4.2. Radiopharmaceuticals and nuclear oncology expand
3.4.3. Digital specialty pharmacy and adherence programs rise
Chapter No. 4: Competition Analysis
4.1. Company Market Share Analysis
4.1.1. North America Anticancer Drugs/Oncology Drugs Market Company Revenue Market Share, 2025
4.2. Strategic Developments
4.3. Competitive Dashboard
4.4. Company Assessment Metrics, 2025
Chapter No. 5: North America Market Analysis, Insights and Forecast, by Drug Class
Chapter No. 6: North America Market Analysis, Insights and Forecast, by Indication
Chapter No. 7: North America Market Analysis, Insights and Forecast, by Distribution Channel
Chapter No. 8: North America Market Analysis, Insights and Forecast, by Geography
8.1. United States
8.2. Canada
8.3. Mexico
Chapter No. 9: Company Profile
9.1. AstraZeneca plc
9.2. Novartis AG
9.3. Merck & Co., Inc.
9.4. Amgen
9.5. Pfizer Inc.
9.6. AbbVie Inc.
9.7. Astellas Pharma Inc.
9.8. F. Hoffmann-La Roche Ltd.
9.9. Johnson & Johnson
9.10. Bristol-Myers Squibb Company
List of Figures
Fig No. 1: North America Anticancer Drugs/Oncology Drugs Market Revenue Share, by Drug Class, 2025 and 2032
Fig No. 2: Market Attractiveness Analysis, by Drug Class
Fig No. 3: Incremental Revenue Growth Opportunity by Drug Class, 2025–2032
Fig No. 4: North America Anticancer Drugs/Oncology Drugs Market Revenue Share, by Indication, 2025 and 2032
Fig No. 5: Incremental Revenue Growth Opportunity by Indication, 2025–2032
Fig No. 6: North America Anticancer Drugs/Oncology Drugs Market Revenue Share, by Distribution Channel, 2025 and 2032
Fig No. 7: North America Anticancer Drugs/Oncology Drugs Market Revenue Share, by Geography, 2025 and 2032
Fig No. 8: Market Attractiveness Analysis, by Geography
List of Tables
Table No. 1: North America Anticancer Drugs/Oncology Drugs Market Revenue, by Drug Class, 2021–2025 (USD MN)
Table No. 2: North America Anticancer Drugs/Oncology Drugs Market Revenue, by Drug Class, 2026–2032 (USD MN)
Table No. 3: North America Anticancer Drugs/Oncology Drugs Market Revenue, by Indication, 2021–2025 (USD MN)
Table No. 4: North America Anticancer Drugs/Oncology Drugs Market Revenue, by Indication, 2026–2032 (USD MN)
Table No. 5: North America Anticancer Drugs/Oncology Drugs Market Revenue, by Distribution Channel, 2021–2025 (USD MN)
Table No. 6: North America Anticancer Drugs/Oncology Drugs Market Revenue, by Distribution Channel, 2026–2032 (USD MN)
Table No. 7: North America Anticancer Drugs/Oncology Drugs Market Revenue, by Geography, 2021–2025 (USD MN)
Table No. 8: North America Anticancer Drugs/Oncology Drugs Market Revenue, by Geography, 2026–2032 (USD MN)
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the current market size for the North America Anticancer Drugs/Oncology Drugs Market and what is its projected size in 2032?
The North America Anticancer Drugs/Oncology Drugs Market was valued at USD 87,086.19 MN in 2025 and is projected to reach USD 150,370.53 MN by 2032.
At what CAGR is the North America Anticancer Drugs/Oncology Drugs Market projected to grow?
The North America Anticancer Drugs/Oncology Drugs Market is projected to grow at a CAGR of 6.76% during the forecast period.
Which drug class segment is expected to lead the market?
Targeted Therapy is expected to hold a strong position, supported by biomarker-led prescribing, companion diagnostics and precision medicine adoption.
Which indication segment supports strong market demand?
Lung Cancer supports strong market demand because it has high use of chemotherapy, targeted therapy, immunotherapy and combination regimens.
Which distribution channel holds the strongest position?
Hospital Pharmacies hold the strongest position because many oncology therapies require infusion administration, clinical monitoring and controlled handling.
Who are the leading companies in the market?
The leading companies include AstraZeneca plc, Novartis AG, Merck & Co., Inc., Amgen, Pfizer Inc., AbbVie Inc., Astellas Pharma Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson and Bristol-Myers Squibb Company.
Which geography leads the North America market?
The United States leads the North America market due to its large treated patient base, strong oncology research ecosystem, broad cancer center network and high adoption of premium therapies.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The DNA Forensics Market size was estimated at USD 6,940.47 million in 2025 and is expected to reach USD 11,601.47 million by 2032, growing at a CAGR of 8.94% from 2025 to 2032.
The global healthcare POS terminals market was valued at USD 16,218 million in 2024 and is projected to reach USD 35,840.49 million by 2032, expanding at a compound annual growth rate (CAGR) of 10.42% during the forecast period, according to Credence Research.
The global healthcare analytical testing market was valued at USD 8,183 million in 2024 and is projected to reach USD 18,870.73 million by 2032, expanding at a compound annual growth rate (CAGR) of 11.01% during the forecast period,
The Global Optogenetics market size was valued at USD 118 million in 2024 and is anticipated to reach USD 180.24 million by 2032, growing at a CAGR of 5.46% during the forecast period.
The glycated albumin assay market was valued at USD 613 million in 2024 and is projected to reach USD 1,135.21 million by 2032, registering a CAGR of 8% during the forecast period.
The pregelatinized starch market reached USD 3,344.5 million in 2024 and is projected to reach USD 4,626.7 million by 2032, growing at a CAGR of 4.14% during the forecast period. (Credence Research)
The pregnancy detection kits market reached USD 1,694.5 million in 2024 and is projected to reach USD 2,541.95 million by 2032, growing at a CAGR of 5.2% during the forecast period.
The Magnetic Resonance Imaging (MRI) market was valued at USD 7094.5 million in 2024 and is anticipated to reach USD 11566.13 million by 2032, growing at a CAGR of 6.3% during the forecast period.
Cell Cytometry market size was valued USD 5,659 Million in 2024 and is anticipated to reach USD 10,319.51 Million by 2032, at a CAGR of 7.8% during the forecast period.
Blood Meal Market size was valued USD 8,920 Million in 2024 and is anticipated to reach USD 14,542.23 Million by 2032, at a CAGR of 6.3% during the forecast period.
The Audiology Devices market size reached USD 14,763 million in 2024. It is expected to reach USD 23,655.31 million by 2032, at a CAGR of 6.07% during the forecast period.
The diagnostic specialty antibodies market was valued at USD 4,093 million in 2024 and is projected to reach USD 7,860.6 million by 2032, expanding at a compound annual growth rate (CAGR) of 8.5% during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$3999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$4999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
